Kereskedés Biora Therapeutics Inc. - BIOR CFD

Biora Therapeutics Inc., formerly Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.